Sudden Deafness in a Patient with Chronic Hepatitis C Treated with Peginterferon and Ribavirin Combination Therapy.
10.3904/kjm.2015.88.3.288
- Author:
Gun Woo PARK
1
;
Hyoung Yeol PARK
;
Eui Kyeong BANG
;
Jun Ho JO
;
Min Woong JEONG
;
Song Hee OH
Author Information
1. Department of Internal Medicine, Busan Veterans Hospital, Busan, Korea. z-zone13@hanmail.net
- Publication Type:Case Report
- Keywords:
Hepatitis C, Chronic;
Peginterferon alfa-2a;
Ribavirin;
Hearing loss, Sudden
- MeSH:
Audiometry, Pure-Tone;
Female;
Hearing;
Hearing Loss;
Hearing Loss, Sensorineural;
Hearing Loss, Sudden*;
Hepacivirus;
Hepatitis C, Chronic*;
Humans;
Middle Aged;
Retreatment;
Ribavirin*;
RNA
- From:Korean Journal of Medicine
2015;88(3):288-293
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Combined peginterferon and ribavirin therapy for chronic hepatitis C is associated with several adverse side effects, but sudden deafness is uncommon. Here we report the case of a 62-year-old female with chronic hepatitis C (genotype 1b) who developed sudden deafness after completing 12 months of treatment with peginterferon alpha2a (180 microg/week) and ribavirin (1,000 mg/day). Pure-tone audiometry revealed a right-sided sensorineural hearing loss, which did not respond to 2 weeks of systemic corticosteroid therapy. Six months after the end of treatment for chronic hepatitis C, her qualitatively determined hepatitis C virus RNA level was 121,000 IU/mL. Following therapeutic failure, the patient was observed without retreatment for chronic hepatitis C or her hearing loss for a period of 12 months, during which time her hearing recovered almost completely.
